Orally active aminopeptidase A inhibitors reduce blood pressure: A new strategy for treating hypertension

Hypertension

Volumn 51, Issue 5, 2008, Pages 1318-1325

  Bodineau, Laurence ^a,b,c   Frugière, Alain ^a,b,c   Marc, Yannick ^a,c   Inguimbert, Nicolas ^a,d   Fassot, Céline ^a,b,c   Balavoine, Fabrice ^e   Roques, Bernard ^a,d   Llorens Cortes, Catherine ^a,b,c  

^a INSERM   (France)

^b Centre de Recherche Interdisciplinaire en Biologie   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Quantum Genomics   (France)

Author keywords

Aminopeptidase A inhibitors; Blood pressure; Brain renin angiotensin system; DOCA salt rats; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGIPRESSIN; EC 33; ENZYME INHIBITOR; GLUTAMYL AMINOPEPTIDASE; RB 150; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DIURESIS; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FLUID INTAKE; HYPERTENSION; IN VITRO STUDY; KALIURESIS; MALE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ARGININE VASOPRESSIN; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DISULFIDES; DIURESIS; DRINKING; ENZYME INHIBITORS; GLUTAMYL AMINOPEPTIDASE; HYPERTENSION; MALE; RATS; RATS, INBRED DAHL; RATS, INBRED WKY; SULFONIC ACIDS;

EID: 39649093737     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.098772     Document Type: Article

References (48)

1. Corvol P, Plouin PF. Angiotensin II receptor blockers: current status and future prospects. Drugs. 2002;62:53-64.
2. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
3. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 1994;34:891-894.
4. Fried MR, Eastlund T, Christie B, Mullin GT, Key NS. Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion. 1996;36:900-903.
5. Holm EA, Randlov A, Strandgaard S. Brief report: acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. Blood Press. 1996;5:360-362.
6. Saine DR, Ahrens ER. Renal impairment associated with losartan. Ann Intern Med. 1996;124:775.
7. Johansen TL, Kjaer A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrol. 2001;2:1.
8. Saunders EJ, Saunders JA. Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int. 1990;11:423-432.
9. Radevski I, Skudicky D, Candy G, Sathekge S, Strugo V, Sareli P. Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Am J Hypertens. 1999;12:194-203.
10. Ganten D, Hermann K, Bayer C, Unger T, Lang RE. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science. 1983;221:869-871.
11. Reaux A, de MN, Zini S, Cadel S, Fournie-Zaluski MC, Roques BP, Corvol P, Llorens-Cortes C. PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III. Neuroendocrinology. 1999;69:370-376.
12. Oparil S, Chen YF, Berecek KH, Calhoun DA, Wyss JM. The role of central nervous system in hypertension. In: Laragh JH and Brenner BM, eds. Hypertension: Pathology, Diagnosis and Management. New York, NY: Raven; 1995:713-740.
13. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-346.
14. Douglas JG. Angiotensin receptor subtypes of the kidney cortex. Am J Physiol. 1987;253:F1-F7.
15. Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept. 1995;59:269-295.
16. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol. 1987;49:413-435.
17. Wright JW, Harding JW. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Brain Res Rev. 1997;25:96-124.
18. Chauvel EN, Coric P, Llorens-Cortes C, Wilk S, Roques BP, Fournie-Zaluski MC. Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors. J Med Chem. 1994;37:1339-1346.
19. Fournie-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP. "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J Med Chem. 1992;35:2473-2481.
20. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A. 1996;93:11968-11973.
21. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A. 1999;96:13415-13420.
22. Morton JJ, Casals-Stenzel J, Lever AF, Millar JA, Riegger AJ, Tree M. Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor. Br J Clin Pharmacol. 1979;7:233S-241S.
23. Itaya Y, Suzuki H, Matsukawa S, Kondo K, Saruta T. Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats. Am J Physiol. 1986;251:H261-H268.
24. Fournie-Zaluski MC, Fassot C, Valentin B, Djordjijevic D, Reaux-Le GA, Corvol P, Roques BP, Llorens-Cortes C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc Natl Acad Sci U S A. 2004;101:7775-7780.
25. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab. 2001;12:157-162.
26. Wright JW, Tamura-Myers E, Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, Harding JW. Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R725-R733.
27. Kokje RJ, Wilson WL, Brown TE, Karamyan VT, Wright JW, Speth RC. Central pressor actions of aminopeptidase-resistant angiotensin II analogs: challenging the angiotensin III hypothesis. Hypertension. 2007;49:1328-1335.
28. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515-521.
29. Zini S, Masdehors P, Lenkei Z, Fournie-Zaluski MC, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Neuroscience. 1997;78:1187-1193.
30. Iturrioz X, Vazeux G, Celerier J, Corvol P, Llorens-Cortes C. Histidine 450 plays a critical role in catalysis and, with Ca2+, contributes to the substrate specificity of aminopeptidase A. Biochemistry. 2000;39:3061-3068.
31. Schalk C, d'Orchymont H, Jauch MF, Tarnus C. 3-Amino-2-tetralone derivatives: novel potent and selective inhibitors of aminopeptidase-M (EC 3.4.11.2). Arch Biochem Biophys. 1994;311:42-46.
32. Tieku S, Hooper NM. Inhibition of aminopeptidases N, A and W: a re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzyme. Biochem Pharmacol. 1992;44:1725-1730.
33. Gaudet E, Blanc J, Elghozi JL. Role of angiotensin II and catecholamines in blood pressure variability responses to stress in SHR. Am J Physiol. 1996;270:R1265-R1272.
34. Vazeux G, Wang J, Corvol P, Llorens-Cortes C. Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A. J Biol Chem. 1996;271:9069-9074.
35. Rozenfeld R, Iturrioz X, Maigret B, Llorens-Cortes C. Contribution of molecular modeling and site-directed mutagenesis to the identification of two structural residues, Arg-220 and Asp-227, in aminopeptidase A. J Biol Chem. 2002;277:29242-29252.
36. Inguimbert N, Coric P, Dhotel H, Bonnard E, Llorens-Cortes C, Mota N, Fournie-Zaluski MC, Roques BP. Synthesis and in vitro activities of new non-peptidic APA inhibitors. J Pept Res. 2005;65:175-188.
37. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol (Berl). 1984;62:178-184.
38. Lin KS, Chan JY, Chan SH. Involvement of AT2 receptors at NRVL in tonic baroreflex suppression by endogenous angiotensins. Am J Physiol. 1997;272:H2204-H2210.
39. Ross CA, Ruggiero DA, Park DH, Joh TH, Sved AF, Fernandez-Pardal J, Saavedra JM, Reis DJ. Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate, and plasma catecholamines and vasopressin. J Neurosci. 1984;4:474-494.
40. Brown DL, Guyenet PG. Electrophysiological study of cardiovascular neurons in the rostral ventrolateral medulla in rats. Circ Res. 1985;56:359-369.
41. Zini S, Demassey Y, Fournie-Zaluski MC, Bischoff L, Corvol P, Llorens-Cortes C, Sanderson P. Inhibition of vasopressinergic neurons by central injection of a specific aminopeptidase A inhibitor. Neuroreport. 1998;9:825-828.
42. Nishimura M, Ohtsuka K, Sakamoto M, Nanbu A, Takahashi H, Yoshimura M. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. J Hypertens. 1998;16:1175-1185.
43. Masuyama Y, Tsuda K, Kuchii M, Nishio I. Peripheral neural mechanism of hypertension in rat models-peripheral sympathetic neurotransmission in hypertension. J Hypertens. 1986;4:S189-S192.
44. Saavedra JM. Brain and pituitary angiotensin. Endocr Rev. 1992;13:329-380.
45. Wright JW, Quirk WS, Hanesworth JM, Harding JW. Influence of aminopeptidase inhibitors on brain angiotensin metabolism and drinking in rats. Brain Res. 1988;441:215-220.
46. Yang CC, Chan SH, Chan JY. Physiological Role of Brain Angiotensin III in Drinking Behavior in the Rat. J Biomed Sci. 1996;3:203-210.
47. Faber F, Gembardt F, Sun X, Mizutani S, Siems WE, Walther T. Lack of angiotensin II conversion to angiotensin III increases water but not alcohol consumption in aminopeptidase A-deficient mice. Regul Pept. 2006;136:130-137.
48. Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, Harding JW, Wright JW. Roles of brain angiotensins II and III in thirst and sodium appetite. Brain Res. 2005;1060:108-117.